ClinicalTrials.gg
CompletedNCT04493502Updated Apr 28, 2023Results posted

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

A Phase 2 interventional study of Placebo and LY3041658 in Hidradenitis Suppurativa, sponsored by Eli Lilly and Company. Completed at 20 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
61st of 139
72 · median 45
Started
2020
with 15 others
Phase 2
61 of 161
11 open now
Registered
65th of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 61st largest by enrollment of the 139 interventional ones that give a count, is one of 16 that started in 2020, is one of 61 in phase 2, and was the 65th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of HS for at least 6 months
  • Have HS lesions in at least 2 different anatomic areas
  • Have inadequate response or intolerance to a 28 day course of oral antibiotics
  • Have a total count of abscesses and inflammatory nodules greater than or equal to 4
  • Agree to use a topical antiseptic daily
  • Agree to stop using topical antibiotics during the study. In certain cases, oral antibiotics will be allowed

Exclusion criteria

Exclusion Criteria:

  • Have more than 20 draining fistulae
  • Have received any biologic medication (adalimumab, etc.) for the treatment of HS
  • Plan to use oral opioids for HS-related pain during the study
  • Uncontrolled depression or suicidal thoughts
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    LY3041658

    Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W).

    Drug: LY3041658

  • Placebo comparator
    Placebo

    Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16.

    Drug: Placebo · Drug: LY3041658

Interventions

  • DrugPlacebo

    Administered IV

  • Administered IV

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16

    The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.

    Time frame: Week 16

Secondary outcomes

  1. Mean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count

    Mean Change from baseline in total AN count at Week 16 was reported. Abscess and inflammatory nodule were counted for the Hidradenitis Suppurativa (HS) affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.

    Time frame: Baseline, Week 16

  2. Mean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS)

    The Skin Pain - HS Numeric Rating Scale (NRS) is a patient-administered, single-question, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no skin pain" and 10 representing "skin pain as bad as you can imagine." The recall period is 7 days.

    Time frame: Baseline, Week 16

07

Results

Posted Apr 28, 2023

Participant flow

Double Blind Treatment (Week 0 - 16)
Participant flow — Double Blind Treatment (Week 0 - 16)
MilestonePlacebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658
Started2448
Received at least one dose of study drug2245
Completed1438
Not completed1010
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up34
Withdrew: Other, relocation01
Withdrew: Other, protocol deviation01
Withdrew: Physician decision10
Withdrew: Withdrawal by subject31
Withdrew: Randomized but never treated23
Open-label Extension (Week 16 - 36)
Participant flow — Open-label Extension (Week 16 - 36)
MilestonePlacebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658
Started1438
Received at least one dose of study drug1336
Completed1029
Not completed49
Withdrew: Lost to follow-up10
Withdrew: Physician decision01
Withdrew: Withdrawal by subject38
Post-treatment Follow-up (10 Weeks)
Participant flow — Post-treatment Follow-up (10 Weeks)
MilestonePlacebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658
Started1029
Completed824
Not completed25
Withdrew: Lost to follow-up01
Withdrew: Physician decision01
Withdrew: Withdrawal by subject23

Outcome measures

PrimaryPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16

The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
percentage of participantsPlacebo600 mg LY3041658
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 1631.8 (12.4 to 51.3)48.9 (34.3 to 63.5)
Statistical analysis
  • Placebo vs 600 mg LY3041658 · Regression, Logistic · p = 0.189 · Mean difference (final values): 17.1 · 95% CI -7.3 to 41.4
SecondaryMean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count

Mean Change from baseline in total AN count at Week 16 was reported. Abscess and inflammatory nodule were counted for the Hidradenitis Suppurativa (HS) affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · count of abscess and inflammatory nodule
Mean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count
count of abscess and inflammatory nodulePlacebo600 mg LY3041658
Mean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count-1.85 ± 1.636-6.52 ± 1.133
Statistical analysis
  • Placebo vs 600 mg LY3041658 · ANCOVA · p = 0.024 · Mean difference (final values): -4.67 · 95% CI -8.69 to -0.64
SecondaryMean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS)

The Skin Pain - HS Numeric Rating Scale (NRS) is a patient-administered, single-question, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no skin pain" and 10 representing "skin pain as bad as you can imagine." The recall period is 7 days.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS)
units on a scalePlacebo600 mg LY3041658
Mean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS)-1.83 ± 0.614-1.78 ± 0.418
Statistical analysis
  • Placebo vs 600 mg LY3041658 · ANCOVA · p = 0.949 · Mean difference (final values): 0.05 · 95% CI -1.44 to 1.53

Adverse events

Collected over Baseline Up to Follow-up Period (46 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
600 mg LY3041658 _Double-Blind Treatment Period0/45 (0%)0/45 (0%)10/45 (22.2%)
Placebo_Double-Blind Treatment Period0/22 (0%)2/22 (9.1%)2/22 (9.1%)
600 mg LY3041658_Open-Label Extension0/49 (0%)1/49 (2%)13/49 (26.5%)
Follow-Up Period0/39 (0%)0/39 (0%)2/39 (5.1%)
Most frequent serious events
Most frequent serious events
Event600 mg LY3041658 _Double-Blind Treatment PeriodPlacebo_Double-Blind Treatment Period600 mg LY3041658_Open-Label ExtensionFollow-Up Period
Post procedural infectionInfections and infestations0/451/220/490/39
Aortic stenosisVascular disorders0/451/220/490/39
Atrial fibrillationCardiac disorders0/450/221/490/39
PneumoniaInfections and infestations0/450/221/490/39
Most frequent other events
Most frequent other events
Event600 mg LY3041658 _Double-Blind Treatment PeriodPlacebo_Double-Blind Treatment Period600 mg LY3041658_Open-Label ExtensionFollow-Up Period
Covid-19Infections and infestations2/451/225/491/39
BalanoposthitisReproductive system and breast disorders1/100/100/120/11
Scrotal operationSurgical and medical procedures0/101/100/120/11
NasopharyngitisInfections and infestations0/450/224/490/39
ConstipationGastrointestinal disorders3/450/220/490/39
NauseaGastrointestinal disorders3/450/220/491/39
FatigueGeneral disorders3/450/220/490/39
ArthralgiaMusculoskeletal and connective tissue disorders3/450/222/490/39
Upper respiratory tract infectionInfections and infestations0/450/223/490/39

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Placebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658Total
Mean36.10 ± 12.6837.10 ± 12.3836.80 ± 12.39
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658Total
Female123547
Male101020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658Total
Hispanic or Latino6713
Not Hispanic or Latino153550
Unknown or Not Reported134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American51217
White163046
More than one race123
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Placebo/600 mg LY3041658600 mg LY3041658 / 600 mg LY3041658Total
Australia257
United States204060
08

Study locations

20 sites
  • Northwest Arkansas Clinical Trials Center
    Rogers, Arkansas 72758, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Skin Care Research, Inc
    Hollywood, Florida 33021, United States
  • Nova Clinical Research, LLC
    Miami, Florida 33125, United States
  • ForCare Clinical Research
    Tampa, Florida 33613-1244, United States
  • Marietta Dermatology Clinical Research
    Marietta, Georgia 30060, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Allcutis Research, Inc.
    Beverly, Massachusetts 01915, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • ALLCUTIS Research
    Portsmouth, New Hampshire 03801, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • UC Physicians Office Dermatology
    Cincinnati, Ohio 45267, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Westmead Hospital
    Northmead, New South Wales 2152, Australia
  • Sunshine Coast University Hospital
    Birtinya, QID 4575, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 03050, Australia
  • Fremantle Dermatology
    Fremantle, Western Australia 6160, Australia
  • Holdsworth House Medical Practice
    Sydney, 2010, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Mar 2022, 18 months.

Results were first posted in Apr 2023, 1 year 1 month after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 18 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2020
First posted
Jul 30, 2020
StartActual
Aug 26, 2020
Primary completionActual
Mar 15, 2022
CompletionActual
Oct 13, 2022
Results first posted
Apr 28, 2023
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04493502
Responsible party
Sponsor
First posted
Jul 30, 2020
Start date
Aug 26, 2020
Primary completion
Mar 15, 2022
Completion
Oct 13, 2022
Results posted
Apr 28, 2023
Last update
Apr 28, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrekibart

Start the discussion